A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma
- Registration Number
- NCT01667419
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in participants with completely resected, cutaneous BRAF mutation-positive melanoma at high risk for recurrence. Participants will be enrolled in two separate cohorts: Cohort 1 will include participants with completely resected Stage IIC, IIIA (participants with one or more nodal metastasis greater than \[\>\] 1 millimeter \[mm\] in diameter), or IIIB cutaneous melanoma, as defined by the American Joint Committee on Cancer (AJCC) Classification, Version 7; Cohort 2 will include participants with Stage IIIC cutaneous melanoma, as defined by this classification scheme. Within each cohort, participants will be randomized (1:1 ratio) to receive vemurafenib or matching placebo over a 52-week period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 498
- Histologically confirmed melanoma of cutaneous origin
- Participants with BRAFV600 mutation-positive, cutaneous melanoma (either pathologic Stage IIC or Stage III according to AJCC Staging Criteria version 7 that has been completely resected
- BRAF V600 mutation status of the current primary tumor or involved lymph node determined to be positive using the cobas BRAF V600 mutation test
- Surgically rendered free of disease within 90 days of randomization
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 5 years
- Fully recovered from the effects of any major surgery or significant traumatic injury prior to the first dose of study treatment
- Adequate hematologic, hepatic, and renal function
- History of any systemic or local therapy (e.g., chemotherapy, biologic or targeted therapy, hormonal therapy, or photodynamic therapy) for the treatment or prevention of melanoma, including interferon alpha-2b and pegylated interferon alpha-2b
- History of limb perfusion therapy
- History of radiotherapy for the treatment of melanoma
- Invasive malignancy other than melanoma at the time of enrollment or within 5 years prior to first dose of study treatment
- Family history of inherited colon cancer syndromes
- Known personal history of >3 adenomatous colorectal polyps or a personal history of adenomatous colorectal polyp(s) >2 centimeters (cm) in size
- History of or current clinical, radiographic, or pathologic evidence of in-transit metastases, satellite, or microsatellite lesions
- History of or current clinical, radiographic, or pathologic evidence of recurrent lymph node involvement after resection of a primary melanoma with lymph node involvement at any time in the past
- History of local and/or regional and/or distant melanoma recurrence
- History or current radiographic or pathologic evidence of distant metastases
- History of clinically significant cardiac or pulmonary dysfunction
- Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study treatment
- Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort 1 Vemurafenib Vemurafenib Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 milligrams (mg) twice daily, in 28-day cycles, for up to 52 weeks Cohort 1 Placebo Placebo Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks Cohort 2 Placebo Placebo Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks Cohort 2 Vemurafenib Vemurafenib Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks
- Primary Outcome Measures
Name Time Method Disease-Free Survival (DFS) as Assessed Using Contrast-Enhanced Magnetic Resonance Imaging (MRI) or Contrast Enhanced Computed Tomography (CT) From randomization until the date of the first local, regional, or distant melanoma recurrence, occurrence of new primary melanoma, or death from any cause (up to the April 17, 2017 data cut-off, approximately 4.5 years) DFS was defined as the time from randomization until the date of the first local, regional, or distant melanoma recurrence, occurrence of new primary melanoma, or death from any cause.
- Secondary Outcome Measures
Name Time Method Distant Metastasis-Free Survival (DMFS) as Assessed Using Contrast-Enhanced MRI or Contrast Enhanced CT From randomization until the date of diagnosis of distant (i.e., non-locoregional) metastases or death from any cause (up to the April 17, 2017 data cut-off, approximately 4.5 years) DMFS was defined as the time from randomization until the date of diagnosis of distant (i.e. non-locoregional) metastases or death from any cause.
Overall Survival (OS) From randomization until the date of death from any cause (up until 13-July-2018, approximately 6 years) OS is defined as the time from randomization until the date of death from any cause.
Percentage of Participants With Adverse Events From randomization up to study completion or discontinuation (up until 13-July-2018, approximately 6 years) An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) 30-Item Quality of Life Questionnaire (QLQ-C30) Score Day 1, Day 8, Day 15, Day 22 of Cycle 1;Day 1, Day 15 of Cycle 2;Day 1 Cycles 3-13;end of treatment(up to 13 months);every 13 weeks thereafter until recurrence or occurrence of a new primary melanoma (up to 17-Apr-17 data cut-off,approximately 4.5 years) European Organisation for Research and Treatment of Cancer 30-Item Quality of Life Questionnaire assesses 8 symptoms, function, financial difficulties, and a global health status/health-related quality of life (HRQoL). Most questions use a 4-point scale (1 'Not at all' to 4 'Very much';2 questions use a 7-point scale (1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. Higher scores for the function and HRQoL represent higher levels of functioning and HRQoL, higher scores for the symptom represent higher levels of symptoms/problems, higher score for financial difficulty represent higher level of perceived financial burden of treatment. Changes of 5-10 points are considered to represent a minimally important difference to participants. A positive value means an increase, and negative value means a decrease in score at the indicated time-point relative to the score at baseline (Cycle 1 Day 1).
Plasma Concentration of Vemurafenib Pre-morning dose (0 hour [hr]) and 1 to 4 hrs post-dose on Days 1, 8, 15, and 22 of Cycle 1; pre-morning dose (0 hr) on Days 1 and 15 of Cycle 2; pre-morning dose (0 hr) on Day 1 of Cycles 3-13; at end of treatment (up to 13 months)
Trial Locations
- Locations (206)
Krasnodar City Oncology Center
🇷🇺Krasnodar, Russian Federation
Military Medical Academy
🇷🇸Belgrade, Serbia
Mary Potter Oncology Centre
🇿🇦Groenkloof, South Africa
Groote Schuur Hospital Radiation Oncology Department; Department of Radiation Oncology
🇿🇦Observatory, South Africa
Hospital Clinico Universitario de Santiago
🇪🇸Santiago de Compostela, LA Coruña, Spain
Institut Catala d Oncologia Hospital Duran i Reynals
🇪🇸Barcelona, Spain
Guys and St Thomas NHS Foundation Trust, Guys Hospital
🇬🇧London, United Kingdom
University of Pretoria Oncology Department
🇿🇦Pretoria, South Africa
Hospital Costa del Sol; Servicio de Oncologia
🇪🇸Marbella, Malaga, Spain
Scientific Research Oncology Institute named after N.N. Petrov
🇷🇺St. Petersburg, Russian Federation
Addenbrooke's Hospital
🇬🇧Cambridge, United Kingdom
Sandton Oncology Medical Group
🇿🇦Sandton, South Africa
GVI Rondebosch Oncology Centre
🇿🇦Cape Town, South Africa
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
UCLA Hematology Oncology - Irvine
🇺🇸Irvine, California, United States
Kaiser Permanente
🇺🇸San Francisco, California, United States
The Angeles Clinic and Research Institute - W LA Office
🇺🇸Los Angeles, California, United States
Cancer Center Of Santa Barbara; Network Clinical Research Specialist
🇺🇸Los Angeles, California, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
Mary Babb Randolph Cancer Center
🇺🇸Morgantown, West Virginia, United States
TRIO-US Network Administration; Network Clinical Research Specialist
🇺🇸Los Angeles, California, United States
UCLA Cancer Center Hema/Oncol
🇺🇸Valencia, California, United States
Kaiser Permanente - Vallejo
🇺🇸Vallejo, California, United States
Memorial Healthcare System
🇺🇸Hollywood, Florida, United States
University of Pennsylvania Health System
🇺🇸Philadelphia, Pennsylvania, United States
Oncology Specialists, S.C.
🇺🇸Park Ridge, Illinois, United States
Indiana University Department of Medicine; Division of Infectious Diseases
🇺🇸Indianapolis, Indiana, United States
Barbara Ann Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Chris O'Brien Lifehouse
🇦🇺Camperdown, New South Wales, Australia
Fiona Stanley Hospital
🇦🇺Murdoch, Western Australia, Australia
Saint John Regional Hospital; Department of Oncology
🇨🇦Saint John, New Brunswick, Canada
Princess Margaret Hospital; Department of Med Oncology
🇨🇦Toronto, Ontario, Canada
Istituto Nazionale Tumori Fondazione G. Pascale
🇮🇹Napoli, Campania, Italy
Länssjukhuset Ryhov
🇸🇪Jönköping, Sweden
Centrallasarettet Växjö
🇸🇪Växjö, Sweden
Royal Cornwall Hospital
🇬🇧Truro, United Kingdom
Velindre Cancer Centre
🇬🇧Cardiff, United Kingdom
Western General Hospital
🇬🇧Edinburgh, United Kingdom
Nottingham University Hospitals City Campus
🇬🇧Nottingham, United Kingdom
Churchill Hospital
🇬🇧Oxford, United Kingdom
New Cross Hospital
🇬🇧Wolverhampton, United Kingdom
Hôpital Saint-Louis
🇫🇷Paris, France
Hospital de la Santa Creu; i Sant Pau
🇪🇸Barcelona, Spain
Hospital General Universitario Gregorio Marañon
🇪🇸Madrid, Spain
ISIS Clinica Especializada
🇦🇷Santa Fe, Argentina
CHU NANTES - Hôtel Dieu; Pharmacy
🇫🇷Nantes, France
GulfCoast Oncology
🇺🇸Sarasota, Florida, United States
UCSD Moores Cancer Center
🇺🇸La Jolla, California, United States
Kaiser Permanente - Hayward
🇺🇸Hayward, California, United States
UCLA Department of Medicine; Division of Hematology / Oncology
🇺🇸California City, California, United States
UCLA Healthcare/Pasadena Oncology
🇺🇸Pasadena, California, United States
Kaiser Foundation Hospital - Oakland (W. MacArthur)
🇺🇸Oakland, California, United States
Kaiser Permanente - Oakland
🇺🇸Oakland, California, United States
Kaiser Permanente - Roseville
🇺🇸Roseville, California, United States
Coastal Integrative Cancer Care
🇺🇸San Luis Obispo, California, United States
K. Permanente - San Jose
🇺🇸San Jose, California, United States
Kaiser Permanente - South San Francisco
🇺🇸South San Francisco, California, United States
Kaiser Permanente - Santa Clara
🇺🇸Santa Clara, California, United States
St. Mary's Hospital Regional Cancer Center
🇺🇸Grand Junction, Colorado, United States
Indiana University Health; Goshen Center for Cancer Care
🇺🇸Goshen, Indiana, United States
Atlantic Health Systems; Pediatrics
🇺🇸Randolph, New Jersey, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Fundación CIDEA
🇦🇷Buenos Aires, Argentina
New York University Medical Center PRIME; NYU Clinical Cancer Center
🇺🇸New York, New York, United States
Duke University Medical Center; Oncology
🇺🇸Durham, North Carolina, United States
West Clinic
🇺🇸Germantown, Tennessee, United States
Instituto Medico Especializado Alexander Fleming
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Hospital Universitario Austral
🇦🇷Derqui-Pilar, Argentina
Hospital Britanico de Buenos Aires
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Instituto de OncologÃa de Rosario
🇦🇷Rosario, Argentina
Centro de Investigacion Pergamino SA
🇦🇷Pergamino, Argentina
Melanoma Institute Australia
🇦🇺North Sydney, New South Wales, Australia
Calvary Mater Newcastle
🇦🇺Waratah, New South Wales, Australia
Border Medical Oncology
🇦🇺Wodonga, New South Wales, Australia
Southern Medical Day Care Centre
🇦🇺Wollongong, New South Wales, Australia
Royal Adelaide Hospital; Hepatology
🇦🇺Adelaide, South Australia, Australia
Queen Elizabeth Hospital
🇬🇧Kings Lynn, United Kingdom
Launceston General Hospital; Gastroenterology Research
🇦🇺Launceston, Tasmania, Australia
Peninsula Oncology Centre; Frankston Private
🇦🇺Frankston, Victoria, Australia
Alfred Hospital
🇦🇺Melbourne, Victoria, Australia
Klinikum Wels-Grieskirchen
🇦🇹Wels, Austria
ZNA Middelheim
🇧🇪Antwerpen, Belgium
UZ Antwerpen
🇧🇪Edegem, Belgium
Jessa Zkh (Campus Virga Jesse)
🇧🇪Hasselt, Belgium
AZ Groeninge, Apotheek
🇧🇪Kortrijk, Belgium
UZ Gent
🇧🇪Gent, Belgium
Hospital de Caridade de IjuÃ
🇧🇷IjuÃ, RO, Brazil
Trymed Clinical Research
🇧🇷Belo Horizonte, MG, Brazil
Hospital das Clinicas - UFRGS
🇧🇷Porto Alegre, RS, Brazil
Clinica de Oncologia de Porto Alegre - CliniOnco
🇧🇷Porto Alegre, RS, Brazil
CITO - Centro Integrado de Terapia Onco-Hematológica - Hospital da Cidade de Passo Fundo
🇧🇷Passo Fundo, RS, Brazil
BC Cancer Agency Vancouver Centre - PARENT; BC Cancer Agency
🇨🇦Vancouver, British Columbia, Canada
Hospital SÃrio-Libanês
🇧🇷Sao Paulo, SP, Brazil
Saint Boniface General Hospital; Section of Nephrology BG 007
🇨🇦Winnipeg, Manitoba, Canada
The Ottawa Hospital Cancer Center; General Campus
🇨🇦Ottawa, Ontario, Canada
Toronto Sunnybrook Hospital
🇨🇦Toronto, Ontario, Canada
CHUM Hôpital Notre-Dame
🇨🇦Montreal, Quebec, Canada
Mcgill University - Royal Victoria Hospital; Oncology
🇨🇦Montreal, Quebec, Canada
CHUQ - Hôtel-Dieu de Québec
🇨🇦Ste-Foy, Quebec, Canada
General Hospital Pula
ðŸ‡ðŸ‡·Pula, Croatia
Clinical Hospital Center Sestre Milosrdnice
ðŸ‡ðŸ‡·Zagreb, Croatia
Clinical Hospital Centre Zagreb
ðŸ‡ðŸ‡·Zagreb, Croatia
Masarykuv onkologicky ustav
🇨🇿Brno, Czechia
Fakultni nemocnice Hradec Kralove
🇨🇿Hradec Kralove, Czechia
Fakultnà nemocnice Olomouc
🇨🇿Olomouc, Czechia
Fakultni nemocnice Ostrava
🇨🇿Ostrava - Poruba, Czechia
Vseobecna fakultni nemocnice v Praze
🇨🇿Praha 2, Czechia
Nemocnice Na Bulovce
🇨🇿Prague, Czechia
Fakultni nemocnice Kralovske Vinohrady
🇨🇿Praha, Czechia
East Tallinn Central Hospital; Clinic of Internal Medicine
🇪🇪Tallinn, Estonia
North Estonia Medical Centre Foundation
🇪🇪Tallinn, Estonia
CHU Besançon - Hôpital Jean Minjoz
🇫🇷Besançon Cedex, France
Groupe Hospitalier Saint André - Hôpital Saint André
🇫🇷Bordeaux, France
Hôpital Ambroise Paré - Boulogne-Billancourt; Respiratory
🇫🇷Boulogne Billancourt, France
Hopital de la Timone
🇫🇷Marseille, France
Hopital Claude Huriez - CHU Lille
🇫🇷Lille, France
CHU de Rouen Hopital; Service de Neurologie
🇫🇷Rouen, France
CHU Nice - Hopital de l'Archet 2
🇫🇷Nice, France
CHU de Toulouse - Hôpital Larrey
🇫🇷Toulouse, France
Centre Hospitalier Lyon Sud
🇫🇷Pierre Benite, France
Universitaetsklinikum Frankfurt
🇩🇪Frankfurt, Germany
Elbekliniken Buxtehude GmbH
🇩🇪Buxtehude, Germany
Universitätsklinikum Koeln
🇩🇪Koeln, Germany
Universitätsklinikum Essen
🇩🇪Essen, Germany
Universitätsklinikum Heidelberg
🇩🇪Heidelberg, Germany
Universitaetsklinikum Schleswig-Holstein - Campus Kiel; Klinik fuer Allgemeine Innere Medizin
🇩🇪Kiel, Germany
Fachklinik Hornheide
🇩🇪Muenster, Germany
Universitätsklinikum Tübingen
🇩🇪Tuebingen, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz; Apotheke
🇩🇪Mainz, Germany
Soroka Medical Center
🇮🇱Beer Sheva, Israel
Mater Private Hospital
🇮🇪Dublin, Ireland
Rambam Health Care Campus
🇮🇱Haifa, Israel
Hadassah University Hospital - Ein Kerem
🇮🇱Jerusalem, Israel
Rabin Medical Center-Beilinson Campus
🇮🇱Petach Tikva, Israel
Chaim Sheba Medical Center
🇮🇱Ramat Gan, Israel
Azienda Ospedaliera Universitaria Policlinico Tor Vergata
🇮🇹Roma, Lazio, Italy
Tel-Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
IDI-Istituto Dermopatico dell'Immacolata IRCCS
🇮🇹Roma, Lazio, Italy
Istituto Nazionale Tumori Regina Elena IRCCS
🇮🇹Roma, Lazio, Italy
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
🇮🇹Bergamo, Lombardia, Italy
Asst Degli Spedali Civili Di Brescia
🇮🇹Brescia, Lombardia, Italy
Ospedale San Raffaele
🇮🇹Milano, Lombardia, Italy
Istituto Europeo Di Oncologia
🇮🇹Milano, Lombardia, Italy
IRCCS Istituto Clinico Humanitas; Farmacia
🇮🇹Rozzano, Lombardia, Italy
Istituto Tumori Giovanni Paolo II IRCSS; Ospedale Oncologico Bari
🇮🇹Bari, Puglia, Italy
A.O.U. Senese Policlinico Santa Maria Alle Scotte
🇮🇹Siena, Toscana, Italy
Centro Oncologico Belenus
🇲🇽Cuernavaca, Mexico
Centro Regiomontano de Investigación ClÃnica
🇲🇽Monterrey, Mexico
Hospital Civil de Guadalajara Fray Antonio Alcalde
🇲🇽Guadalajara, Mexico
Sanatorio la Luz
🇲🇽Morelia, Mexico
Universitair Medisch Centrum Groningen
🇳🇱Groningen, Netherlands
Christchurch Hospital NZ
🇳🇿Christchurch, New Zealand
Leids Universitair Medisch Centrum; Cardiology
🇳🇱Leiden, Netherlands
SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie
🇵🇱Olsztyn, Poland
Stavanger Universitetssykehus, Helse Stavanger HF
🇳🇴Stavanger, Norway
Wellington Hospital
🇳🇿Wellington, New Zealand
Centrum Onkologii- Instytut; im. M.Skłodowskiej-Curie
🇵🇱Warszawa, Poland
Dolnoslaskie Centrum Onkologii
🇵🇱Wroclaw, Poland
Hospital do Espirito Santo; Servico de Oncologia Medica
🇵🇹Evora, Portugal
IPO de Coimbra; Servico de Oncologia Medica
🇵🇹Coimbra, Portugal
IPO do Porto; Servico de Oncologia Medica
🇵🇹Porto, Portugal
Hospital de Santa Maria; Servico de Oncologia Medica
🇵🇹Lisboa, Portugal
Bristol Haematology and Oncology Centre
🇬🇧Bristol, United Kingdom
Norrlands Universitetssjukhus
🇸🇪Umea, Sweden
Cairns Base Hospital
🇦🇺Cairns, Queensland, Australia
UCLA Hematology Oncology - Westlake
🇺🇸Westlake Village, California, United States
Florida Cancer Specialists - Broadway
🇺🇸Fort Myers, Florida, United States
Stanford University School of Medicine; Stanford Hospital Pharmacy
🇺🇸Stanford, California, United States
Kaiser Permanente - Walnut Creek
🇺🇸Walnut Creek, California, United States
Tennessee Oncology PLLC - Nashville (20th Ave)
🇺🇸Nashville, Tennessee, United States
Klinikum Mannheim GmbH Universitätsklinikum
🇩🇪Mannheim, Germany
The Townsville Hospital; Townsville Cancer Centre
🇦🇺Townsville, Queensland, Australia
Hospital Universitari i Politecnic La Fe
🇪🇸Valencia, Spain
Universitätsklinikum Wurzburg
🇩🇪Würzburg, Germany
Box Hill Hospital
🇦🇺Box Hill, Victoria, Australia
LHSC - Victoria Hospital; Department of Pediatrics
🇨🇦London, Ontario, Canada
St. Josef-Hospital Universitaetsklinikum
🇩🇪Bochum, Germany
Washington University; Dept of Medicine/Div of Medical Oncology
🇺🇸Saint Louis, Missouri, United States
The Mater Misericordiae Hospital
🇮🇪Dublin, Ireland
University College Hospital
🇮🇪Galway, Ireland
Moscow City Oncology Hospital #62
🇷🇺Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation
Institut Jules Bordet
🇧🇪Brussels, Belgium
Clinical Center Bezanijska Kosa
🇷🇸Belgrade, Serbia
CI Dnipropetrovsk CMCH 4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU
🇺🇦Dnipropetrovsk, Ukraine
Lviv State Oncological Regional Treatment and Diagnostic Center
🇺🇦Lviv, Ukraine
Peter Maccallum Cancer Centre
🇦🇺Melbourne, Victoria, Australia
Krankenanstalt Rudolfstiftung Wien
🇦🇹Wien, Austria
Medizinische Universität Wien
🇦🇹Wien, Austria
Cork University Hospital
🇮🇪Cork, Ireland
CHUV; Departement d'Oncologie
🇨ðŸ‡Lausanne, Switzerland
IOV - Istituto Oncologico Veneto IRCCS
🇮🇹Padova, Veneto, Italy
FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
🇷🇺Moscow, Russian Federation
Tartu University Hospital; Clinic of Hematology and Oncology
🇪🇪Tartu, Estonia
Przychodnia Med-Polonia Sp. z o.o.
🇵🇱Poznan, Poland
Institute of Oncology and Radiology of Serbia
🇷🇸Belgrade, Serbia
Institute for oncology of Vojvodina
🇷🇸Sremska Kamenica, Serbia
Istituto Nazionale per la Ricerca sul Cancro di Genova
🇮🇹Genova, Liguria, Italy
Kaiser Permanente Sacramento Medical Center
🇺🇸Sacramento, California, United States
University Of Colorado
🇺🇸Aurora, Colorado, United States
U of L - Physicians Pulmonology; Dept of Neuroradiology and Dept of Diagnostic Radiology
🇺🇸Louisville, Kentucky, United States
St. Luke's Hospital
🇺🇸Kansas City, Missouri, United States
University of Kansas Medical Center; Cancer Center
🇺🇸Kansas City, Missouri, United States
MUSC Hollings Cancer Center/cannon Park Place; Attn: Tamara Saunders
🇺🇸Charleston, South Carolina, United States
General Hospital Varazdin
ðŸ‡ðŸ‡·Varazdin, Croatia
Medizinische Universität Innsbruck
🇦🇹Innsbruck, Austria